Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents

Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents

Introduction: Circulating tumor DNA (ctDNA) monitoring is emerging as a minimally invasive complement to tumor imaging. We evaluated the validity of tissue-agnostic ctDNA quantification across four treatment modalities in NSCLC and SCLC. Methods: Data from consenting patients were collected from ele...

Full description

Saved in:
Bibliographic Details
Main Authors: Anne C. Chiang, MD, PhD, Russell W. Madison, MS, Zoe June Assaf, PhD, Alexander Fine, PhD, Yi Cao, PhD, Ole Gjoerup, PhD, Yanmei Huang, PhD, Dexter X. Jin, PhD, Jason Hughes, PhD, Vladan Antic, MD, PhD, Amanda Young, PhD, David Fabrizio, MS, David Shames, PhD, Sophia Maund, PhD, Alexia Exarchos, MPH, Shailendra Lakhanpal, MD, Richard Zuniga, MD, Lincoln W. Pasquina, PhD, Katja Schulze, PhD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JTO Clinical and Research Reports
Subjects:
ctDNA
Monitoring
Lung cancer
Immunotherapy
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000451
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items